A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
University of Leeds
Oncotherapeutics
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University
Fondazione EMN Italy Onlus
Fred Hutchinson Cancer Center